Spectro-dosemeter-based gamma dose rate network in Germany.

As a consequence of the Chernobyl accident in 1986 the Integrated Measurement and Information System (IMIS) was established (Weiss and Leeb, 1993) which includes on-line monitoring networks for the surveillance of radioactivity in Germany. Today, the German Federal Office for Radiation Protection (BfS) operates a gamma dose rate network with 1800 ambient dose equivalent rate H*(10) (ADER) stations almost equally distributed over the German territory. The ADER network integrates Geiger-Müller (GM) based detectors which, if low and high dose rate tubes are combined, are known to have excellent long-term stability and an extended dose rate range from environmental background level (20 nSv/h) up to several Sv/h.

Analytical and Clinical Sample Performance Characteristics of the Onclarity Assay for the Detection of Human Papillomavirus.

The objective of this study was to determine the result reproducibility and performance of the BD Onclarity human papillomavirus (HPV) assay (Onclarity) on the BD Viper LT platform using both contrived and clinical specimens. Reproducibility was assessed in BD SurePath liquid-based cytology (LBC) medium (SurePath) using contrived panels (HPV genotype 16 [HPV16] positive, HPV18 positive, or HPV45 positive) or clinical specimens (HPV16, -18, -31, -33/58, -45, or -52 positive or HPV negative). In addition, specimens from 3,879 individuals from the Onclarity trial were aliquoted prior to or following cytology processing and tested for HPV.

THE GERMAN DOSE RATE MONITORING NETWORK AND IMPLEMENTED DATA HARMONIZATION TECHNIQUES.

Environmental radiation monitoring networks have been established in Europe and world-wide for the purpose of protecting population and environment against ionizing radiation. Some of these networks had been established during the cold war period and were improved after the Chernobyl accident in 1986. Today, the German Federal Office for Radiation Protection (BfS) operates an early warning network with roughly 1800 ambient dose equivalent rate (ADER) stations equally distributed over the German territory.

Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices.

Background: In the United States, human papillomavirus (HPV) and Papanicolaou (Pap) testing (cotesting) for cervical screening in women ages 30 to 65 years is the preferred strategy, and cytology alone is acceptable. Recently, a proprietary automated test for identifying high-risk HPV types for primary cervical screening was approved by the US Food and Drug Administration. The objective of the current study was to document extensive cervical screening among these screening options.